journal
MENU ▼
Read by QxMD icon Read
search

Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research

journal
https://www.readbyqxmd.com/read/28712631/remembering-a-giant-in-economics-kenneth-j-arrow-1922-2017
#1
Charles E Phelps
No abstract text is available yet for this article.
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28712630/how-to-compare-the-length-of-stay-of-two-samples-of-inpatients-a-simulation-study-to-compare-type-i-and-type-ii-errors-of-12-statistical-tests
#2
Emmanuel Chazard, Grégoire Ficheur, Jean-Baptiste Beuscart, Cristian Preda
BACKGROUND: Although many researchers in the field of health economics and quality of care compare the length of stay (LOS) in two inpatient samples, they often fail to check whether the sample meets the assumptions made by their chosen statistical test. In fact, LOS data show a highly right-skewed, discrete distribution in which most of the observations are tied; this violates the assumptions of most statistical tests. OBJECTIVES: To estimate the type I and type II errors associated with the application of 12 different statistical tests to a series of LOS samples...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28712629/the-prime-diabetes-model-novel-methods-for-estimating-long-term-clinical-and-cost-outcomes-in-type-1-diabetes-mellitus
#3
William J Valentine, Richard F Pollock, Rhodri Saunders, Jay Bae, Kirsi Norrbacka, Kristina Boye
BACKGROUND: Recent publications describing long-term follow-up from landmark trials and diabetes registries represent an opportunity to revisit modeling options in type 1 diabetes mellitus (T1DM). OBJECTIVES: To develop a new product-independent model capable of predicting long-term clinical and cost outcomes. METHODS: After a systematic literature review to identify clinical trial and registry data, a model was developed (the PRIME Diabetes Model) to simulate T1DM progression and complication onset...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28712628/estimating-health-state-utility-values-in-kidney-transplant-recipients-and-waiting-list-patients-using-the-eq-5d-5l
#4
Bernadette Li, John A Cairns, Heather Draper, Christopher Dudley, John L Forsythe, Rachel J Johnson, Wendy Metcalfe, Gabriel C Oniscu, Rommel Ravanan, Matthew L Robb, Paul Roderick, Charles R Tomson, Christopher J E Watson, J Andrew Bradley
OBJECTIVES: To report health-state utility values measured using the five-level EuroQol five-dimensional questionnaire (EQ-5D-5L) in a large sample of patients with end-stage renal disease and to explore how these values vary in relation to patient characteristics and treatment factors. METHODS: As part of the prospective observational study entitled "Access to Transplantation and Transplant Outcome Measures," we captured information on patient characteristics and treatment factors in a cohort of incident kidney transplant recipients and a cohort of prevalent patients on the transplant waiting list in the United Kingdom...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28712627/testing-the-external-validity-of-a-discrete-choice-experiment-method-an-application-to-latent-tuberculosis-infection-treatment
#5
Tima Mohammadi, Nick Bansback, Fawziah Marra, Amir Khakban, Jonathon R Campbell, J Mark FitzGerald, Larry D Lynd, Carlo A Marra
OBJECTIVES: To explore the external validity and predictive power of stated preferences obtained from a discrete choice experiment (DCE) by comparing the predicted behavior of respondents to their actual choices at an individual level. METHODS: A DCE was performed in patients before being offered treatment for latent tuberculosis infection. A mixed logit model was estimated using hierarchical Bayes. The individual-specific preference coefficients were used to calculate the expected probability of choosing the treatment by each patient...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28712626/public-preferences-for-lung-cancer-screening-policies
#6
Henk Broekhuizen, Catharina G M Groothuis-Oudshoorn, Rozemarijn Vliegenthart, Harry Groen, Maarten J IJzerman
BACKGROUND: Because early detection of lung cancer can substantially improve survival, there is increasing attention for lung cancer screening. OBJECTIVES: To estimate public preferences for lung cancer screening and to identify subgroups in preferences. METHODS: Seven important attributes were selected using the literature, interviews, and a panel session. Preferences were elicited using a swing weighting questionnaire. The resulting attribute weights indicate the relative importance of swings from the worst to the best level between attributes...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28712625/impact-of-survey-administration-mode-on-the-results-of-a-health-related-discrete-choice-experiment-online-and-paper-comparison
#7
COMPARATIVE STUDY
Domino Determann, Mattijs S Lambooij, Ewout W Steyerberg, Esther W de Bekker-Grob, G Ardine de Wit
BACKGROUND: Electronic data collection is increasingly being used for discrete choice experiments (DCEs). OBJECTIVES: To study whether paper or electronic administration results in measurement effects. METHODS: Respondents were drawn from the same sample frame (an Internet panel) and completed a nearly identical DCE survey either online or on paper during the same period. A DCE on preferences for basic health insurance served as a case study...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28712624/less-is-more-cross-validation-testing-of-simplified-nonlinear-regression-model-specifications-for-eq-5d-5l-health-state-values
#8
RANDOMIZED CONTROLLED TRIAL
Kim Rand-Hendriksen, Juan Manuel Ramos-Goñi, Liv Ariane Augestad, Nan Luo
BACKGROUND: The conventional method for modeling of the five-level EuroQol five-dimensional questionnaire (EQ-5D-5L) health state values in national valuation studies is an additive 20-parameter main-effects regression model. Statistical models with many parameters are at increased risk of overfitting-fitting to noise and measurement error, rather than the underlying relationship. OBJECTIVES: To compare the 20-parameter main-effects model to simplified, nonlinear, multiplicative regression models in terms of how accurately they predict mean values of out-of-sample health states...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28712623/valid-outcome-measures-in-care-for-older-people-comparing-the-ascot-and-the-icecap-o
#9
COMPARATIVE STUDY
Mariska Q N Hackert, Job van Exel, Werner B F Brouwer
BACKGROUND: Limited health care budgets and population aging result in a need to compare care services on their benefits and costs. Because services for older people often aim to improve multiple life aspects, valid measures are needed to examine their benefits on individuals' health and well-being simultaneously. Two measures may meet this end: the Adult Social Care Outcomes Toolkit (ASCOT) and the ICEpop CAPability measure for Older people (ICECAP-O). OBJECTIVES: To compare the validity of both measures, the ASCOT and the ICECAP-O...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28712622/pharmaceutical-pricing-in-germany-how-is-value-determined-within-the-scope-of-amnog
#10
Victoria Desirée Lauenroth, Tom Stargardt
OBJECTIVES: To analyze how value is determined within the scope of the German Pharmaceutical Restructuring Act, which came into effect in 2011. METHODS: Using data from all pharmaceuticals that had undergone assessment, appraisal, and price negotiations in Germany before June 30, 2016, we applied generalized linear model regression to analyze the impact of added benefit on the difference between negotiated prices and the prices of comparators. Data were extracted from the Federal Joint Committee's appraisals and price databases...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28712621/dealing-with-uncertainty-and-accounting-for-social-value-judgments-in-assessments-of-orphan-drugs-evidence-from-four-european-countries
#11
Elena Nicod, Karen Berg Brigham, Isabelle Durand-Zaleski, Panos Kanavos
OBJECTIVES: To better understand the reasons for differences in reimbursement decisions for orphan drugs in four European countries that were not readily apparent from health technology assessment (HTA) reports and operating procedures. METHODS: Semistructured interviews with representatives of HTA bodies in England, Scotland, Sweden, and France were conducted. An interview topic guide was developed on the basis of findings from a systematic comparison of HTA decisions for 10 orphan drugs...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28712620/a-review-of-empirical-analyses-of-disinvestment-initiatives
#12
REVIEW
James D Chambers, Mark N Salem, Brittany N D'Cruz, Prasun Subedi, Sachin J Kamal-Bahl, Peter J Neumann
BACKGROUND: Disinvesting in low-value health care services provides opportunities for investment in higher value care and thus an increase in health care efficiency. OBJECTIVES: To identify international experience with disinvestment initiatives and to review empirical analyses of disinvestment initiatives. METHODS: We performed a literature search using the PubMed database to identify international experience with disinvestment initiatives...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28712619/ethics-of-informed-consent-for-pragmatic-trials-with-new-interventions
#13
Shona Kalkman, Scott Y H Kim, Ghislaine J M W van Thiel, Diederick E Grobbee, Johannes J M van Delden
OBJECTIVES: Pragmatic trials evaluate the comparative benefits, risks, and burdens of health care interventions in real-world conditions. Such studies are now recognized as valuable to the perimarketing stage of drug development and evaluation, with early pragmatic trials (EPTs) being explored as a means to generate real-world evidence at the time of regulatory market approval. In this article, we present an analysis of the ethical issues involved in informed consent for EPTs, in light of the generally recognized concern that traditional ethical rules governing randomized clinical trials, such as lengthy informed consent procedures, could threaten the "real world" nature of such trials...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28712618/would-a-large-tpa-trial-for-those-4-5-to-6-0-hours-from-stroke-onset-be-good-value-for-information
#14
Djøra I Soeteman, Nicolas A Menzies, Ankur Pandya
OBJECTIVES: To quantify the potential value of new research in patients treated with thrombolytic treatment (tissue-type plasminogen activator [tPA]) in the 4.5- to 6.0-hour time window after stroke onset and to determine the optimal size of a future trial using value of information analysis. METHODS: Expected value of partial perfect and sample information (EVPPI and EVSI) analyses were conducted using a probabilistic Markov model. Data for modified Rankin Scale (mRS) distributions in patients 4...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28712617/cost-effectiveness-analysis-of-an-automated-medication-system-implemented-in-a-danish-hospital-setting
#15
Bettina Wulff Risør, Marianne Lisby, Jan Sørensen
OBJECTIVES: To evaluate the cost-effectiveness of an automated medication system (AMS) implemented in a Danish hospital setting. METHODS: An economic evaluation was performed alongside a controlled before-and-after effectiveness study with one control ward and one intervention ward. The primary outcome measure was the number of errors in the medication administration process observed prospectively before and after implementation. To determine the difference in proportion of errors after implementation of the AMS, logistic regression was applied with the presence of error(s) as the dependent variable...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28712616/aripiprazole-lauroxil-compared-with-paliperidone-palmitate-in-patients-with-schizophrenia-an-indirect-treatment-comparison
#16
REVIEW
Chris Cameron, Jacqueline Zummo, Dharmik N Desai, Christine Drake, Brian Hutton, Ahmed Kotb, Peter J Weiden
BACKGROUND: Aripiprazole lauroxil (AL) is a long-acting injectable atypical antipsychotic recently approved for treatment of schizophrenia on the basis of a large-scale trial of two doses of AL versus placebo. There are no direct-comparison studies with paliperidone palmitate (PP; long-acting antipsychotic used most often in acute settings) for the acute psychotic episode. OBJECTIVES: To indirectly compare efficacy and safety of the pivotal AL study with all PP studies meeting indirect comparison criteria...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28712615/predicting-real-world-effectiveness-of-cancer-therapies-using-overall-survival-and-progression-free-survival-from-clinical-trials-empirical-evidence-for-the-asco-value-framework
#17
Darius N Lakdawalla, Jason Shafrin, Ningqi Hou, Desi Peneva, Seanna Vine, Jinhee Park, Jie Zhang, Ron Brookmeyer, Robert A Figlin
OBJECTIVES: To measure the relationship between randomized controlled trial (RCT) efficacy and real-world effectiveness for oncology treatments as well as how this relationship varies depending on an RCT's use of surrogate versus overall survival (OS) endpoints. METHODS: We abstracted treatment efficacy measures from 21 phase III RCTs reporting OS and either progression-free survival or time to progression endpoints in breast, colorectal, lung, ovarian, and pancreatic cancers...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28712614/what-is-real-world-data-a-review-of-definitions-based-on-literature-and-stakeholder-interviews
#18
REVIEW
Amr Makady, Anthonius de Boer, Hans Hillege, Olaf Klungel, Wim Goettsch
BACKGROUND: Despite increasing recognition of the value of real-world data (RWD), consensus on the definition of RWD is lacking. OBJECTIVES: To review definitions publicly available for RWD to shed light on similarities and differences between them. METHODS: A literature review and stakeholder interviews were used to compile data from eight groups of stakeholders. Data from documents and interviews were subjected to coding analysis. Definitions identified were classified into four categories: 1) data collected in a non-randomized controlled trial setting, 2) data collected in a non-interventional/non-controlled setting, 3) data collected in a non-experimental setting, and 4) others (i...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28712613/patient-reported-outcome-and-observer-reported-outcome-assessment-in-rare-disease-trials
#19
EDITORIAL
Sarah Acaster
No abstract text is available yet for this article.
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28712612/patient-reported-outcome-and-observer-reported-outcome-assessment-in-rare-disease-clinical-trials-an-ispor-coa-emerging-good-practices-task-force-report
#20
Katy Benjamin, Margaret K Vernon, Donald L Patrick, Eleanor Perfetto, Sandra Nestler-Parr, Laurie Burke
BACKGROUND: Rare diseases (RDs) affect a small number of people within a population. About 5000 to 8000 distinct RDs have been identified, with an estimated 6% to 8% of people worldwide suffering from an RD. Approximately 75% of RDs affect children. Frequently, these conditions are heterogeneous; many are progressive. Regulatory incentives have increased orphan drug designations and approvals. OBJECTIVE: To develop emerging good practices for RD outcomes research addressing the challenges inherent in identifying, selecting, developing, adapting, and implementing patient-reported outcome (PRO) and observer-reported outcome (ObsRO) assessments for use in RD clinical trials...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
journal
journal
34615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"